Rania Zayed

Citation:

Omran, D., S. Hamdy, S. Tawfik, S. Esmat, D. ’aA. Saleh, and R. A. Zayed, "Association of Interferon-γ Inducible Protein-10 Pretreatment Level and Sustained Virological Response in HCV-Positive Egyptian Patients.", Annals of Clinical & Laboratory Science, vol. 44, issue 2, pp. 169-174, 2014.

Abstract:

Background. The response to antiviral therapy in HCV infected patients depends on several
predictive factors; however, the ability to achieve sustained virological response is still limited to around
60% of the patients infected with the HCV-4 genotype. Increased serum and intrahepatic interferon -γ
inducible protein 10 (IP-10) levels in patients with chronic hepatitis C have been described. The aim of
the work was to study the impact of pretreatment serum IP-10 level on the antiviral treatment outcome
in a group of Egyptian patients infected with HCV. Materials and methods. The study included 80 treatment
naive HCV patients. Serum IP-10 levels were determined by an enzyme linked immunosorbent assay
before therapy was introduced. Serum samples were examined twice by Real-Time PCR after complete
course of therapy for detection of HCV RNA; at the end of the antiviral therapy and six months later to
detect sustained virological response (SVR). Results. 57 patients (71%) achieved SVR while 23 (29%) patients were non-responders (NR). Pretreatment serum IP-10 levels were significantly lower in patients who achieved SVR than in NR (p=0.000). Conclusion. Low pretreatment serum IP-10 is a favorable predictive of response to antiviral HCV therapy in Egyptian patients.